Regulatory and Ethical Considerations Current Approval Status (2026) As of 2026, neither cagrilintide nor retatrutide has received FDA approval for obesity treatment or metabolic applications
Medically reviewed by Jerome Albert Ecker | MD , Assistant Professor of Medicine, Duke University - Durham, NC on May 20th, 2025
Hydration Reminders Staying hydrated is especially important on GLP-1 medications
Not all peptide products contain the same potency or purity, and not all protocols use concentrations that are adequate for meaningful recovery support
Users typically see wounds close faster, inflammation decrease, and joints regain flexibility within 6-8 weeks
Please be assured that while the exterior packaging may vary, the contents inside are always new and handled with the utmost care